Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells $184,007.68 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Karen M. Anderson sold 10,624 shares of the firm’s stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $17.32, for a total transaction of $184,007.68. Following the sale, the insider now owns 71,525 shares of the company’s stock, valued at approximately $1,238,813. This represents a 12.93 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ CNTA opened at $17.55 on Friday. The stock has a market capitalization of $2.31 billion, a PE ratio of -11.47 and a beta of 1.52. Centessa Pharmaceuticals plc has a fifty-two week low of $6.65 and a fifty-two week high of $18.97. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The business has a fifty day moving average price of $16.62 and a two-hundred day moving average price of $13.51.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. As a group, equities analysts predict that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. HighMark Wealth Management LLC bought a new position in Centessa Pharmaceuticals in the second quarter valued at approximately $840,000. TD Asset Management Inc lifted its stake in Centessa Pharmaceuticals by 40.5% during the second quarter. TD Asset Management Inc now owns 321,168 shares of the company’s stock worth $2,900,000 after purchasing an additional 92,524 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of Centessa Pharmaceuticals by 1.3% in the 2nd quarter. American Century Companies Inc. now owns 935,151 shares of the company’s stock valued at $8,444,000 after purchasing an additional 12,031 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Centessa Pharmaceuticals during the 2nd quarter worth $148,000. Finally, Farallon Capital Management LLC lifted its position in shares of Centessa Pharmaceuticals by 438.0% during the 2nd quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company’s stock worth $18,024,000 after buying an additional 1,625,000 shares during the last quarter. 82.01% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have weighed in on CNTA shares. Morgan Stanley raised shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $11.00 to $26.00 in a report on Thursday, September 19th. Guggenheim increased their target price on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. B. Riley initiated coverage on Centessa Pharmaceuticals in a research note on Thursday, September 19th. They issued a “buy” rating and a $33.00 price target for the company. BMO Capital Markets increased their price objective on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research report on Monday, September 16th. Finally, Jefferies Financial Group boosted their target price on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $25.83.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.